ResMed Inc. (NYSE:RMD – Get Free Report) declared a quarterly dividend on Thursday, April 30th. Stockholders of record on Thursday, May 14th will be paid a dividend of 0.60 per share by the medical equipment provider on Thursday, June 18th. This represents a c) annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, May 14th.
ResMed has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 13 years. ResMed has a payout ratio of 22.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect ResMed to earn $12.10 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 19.8%.
ResMed Stock Performance
Shares of NYSE RMD traded down $11.01 during midday trading on Friday, hitting $202.81. 401,010 shares of the company’s stock were exchanged, compared to its average volume of 1,076,369. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32. The stock’s 50 day moving average price is $233.35 and its 200-day moving average price is $246.69. The firm has a market cap of $29.54 billion, a P/E ratio of 20.13, a PEG ratio of 1.40 and a beta of 0.93. ResMed has a twelve month low of $198.64 and a twelve month high of $293.81.
Key ResMed News
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: Q3 beat and margin expansion — ResMed reported $2.86 EPS vs. $2.79 expected and $1.43B revenue (up ~11% YoY). Gross margins improved ~290 bps and operating income rose, signaling improving unit economics and pricing/volume strength. Resmed Q3 Results
- Positive Sentiment: Cash flow, buybacks and dividend — Operating cash flow was strong ($554M) and the company returned $262M via repurchases/dividends; a $0.60 quarterly dividend (1.1% yield) was declared. These actions support shareholder returns and capital allocation discipline. Resmed Q3 Results
- Neutral Sentiment: CFO transition — CFO Brett Sandercock will retire and Aaron Bloomer has been named his successor; a named successor reduces execution risk but transitions can create short‑term uncertainty. ResMed names new CFO
- Neutral Sentiment: Longer‑term thesis still discussed — Analyst pieces argue stronger profit forecasts and sleep‑apnea market tailwinds could shift ResMed’s narrative, but these are forward‑looking and dependent on execution. Analyst view on forecasts
- Negative Sentiment: Stock sold off despite beats — Commentary and market flow indicate shares slipped after the report; possible drivers include profit‑taking, investor disappointment vs. expectations for bigger upside in guidance or near‑term growth, and rotation out of defensive healthcare names. RMD stock down despite Q3 beat
ResMed Company Profile
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
Featured Stories
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
